Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -0.18% 833.50p 833.50p 834.00p 834.50p 833.50p 834.00p 909,270 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 213.7 3,229.23

Btg Share Discussion Threads

Showing 4951 to 4973 of 6175 messages
Chat Pages: Latest  199  198  197  196  195  194  193  192  191  190  189  188  Older
DateSubjectAuthorDiscuss
06/11/2017
10:54
It was said that to gain growth it needed a joint partnership. Louise will learn her lesson , just because you have a better mouse trap does not mean people will follow your path.
bargainbob
06/11/2017
10:43
Apparently Welstat's complaint was that the sales team was too small to be effective. The Judge agreed. Maybe this is also the problem with the varicose vein treatment.
gregsc
06/11/2017
10:22
Suspect the code pricing is based upon per procedure
gregmorg
06/11/2017
10:13
Next Tuesday should give more insight with reporting and Q andA session. Until then we are just guessing.
bill hunt
06/11/2017
10:00
Though the news is old, but same one, hxxp://www.proactiveinvestors.co.uk/companies/news/184282/btg-shares-fall-as-its-ordered-to-pay-us558mln-in-damages-in-drug-distrubution-dispute-184282.html still price at 900p from Numis Securities
ashehzi
06/11/2017
10:00
The cost of treatment is approx $1500-3000 per procedure. Costs met by the insurer come in at the lower end. If the numbers of treatments don't grow significantly at any time soon, they will have to write Varithena off. Btg are fully valued for now. The loss of the Welstat revenue, several million per year, and was growing. The loss millions from Lemtrada coming off patent. This is not a good news day and £55 million to cough up. I am surprised the market has been so kind.
cockneytrader
06/11/2017
09:51
Noted on Codes, but my question is on the application of payment for multiple veins. Are these rules applicable to multiple veins in the same leg or does it actually apply across both legs? Previous suggested Varithena pricing policies, that I have been aware of, have been on the basis of a single leg and, for all sorts of medical reasons, only one leg could be treated at a time/session with a break of some weeks-if not months before the other leg could be treated. Each leg had been regarded as a separate medical event! So does the Code pricing structure adhere to this one leg principle or does multiple vein treatment actually apply across both legs?
gregmorg
06/11/2017
09:42
Is a treatment , one leg at a time . Could make a big difference on how you read the update. 4 legs can you help lol.
bargainbob
06/11/2017
09:11
It almost like Louise wants the price to be under a certain level . Shocking update on the codes , we will just need to wait till 2018 to see the impact . I suggest getting rid of her to save the time.
bargainbob
06/11/2017
08:44
good to see it recovering back
ashehzi
06/11/2017
08:14
At least this should accelerate growth in Varithena - $3000 against a brick wall is not smart.
weatherman
06/11/2017
07:48
May I remind folk that btg charge $3000 for one can of varithena, yet insurers will only offers $1700 for multiple vein procedure. Shortfall of $1300!
cockneytrader
06/11/2017
07:36
seems like a buying opportunity for some at discounted price then.
ashehzi
06/11/2017
07:17
The good, the bad and the ugly news. Via news. Charges agreed but uncertainty till end of 2018 of impact. Loss of court case and hit of 55 million this half.
bill hunt
06/11/2017
07:15
Shocking! Two awful pieces of news on the same day. Both Products to be written off? Down 10 or maybe 20% on this news.
cockneytrader
05/11/2017
12:34
I can’t see it going much more than £8 but what to I know?
dp1umb
05/11/2017
09:23
Good news indeed dp1umb , maybe a period of golden news nuggets about to be released. Hopefully they can reach a out of court settlement on the recent dispute and move onwards.
bargainbob
05/11/2017
08:59
Bob Zytiga has returned to growth with a 25% increase in sales in the last quarter.
dp1umb
04/11/2017
12:44
Bargain the problem is it’s patent has expired this quarter will be your last revenue unfortunately unless I’ve missed something? I know the zytiga patent is hard to work out but lemtrada was more straight forward. There should also be news soon regarding the lung device which could be earnings enhancing.
dp1umb
04/11/2017
05:42
Think maybe wrong Dave on eye eye eye posted this . I have taken this dater from todays update from Sanofi 3rd quarter sales, and Lemtrada is doing very nicely it's up 5.4% in just this quarter alone . BE HAPPY DAVE , Multiple Sclerosis franchise Net sales (€ million) Q3 2017 Change (CER) 9M 2017 Change (CER) Aubagio® 382 +19.2% 1,178 +26.9%--------------------------------------------------------------------- Lemtrada® 113 +5.4% 362 +18.5%;-------------------------------------------------------------------- Total Multiple Sclerosis 495 +15.7% 1,540 +24.8%.------------------------------------------------ Third-quarter Multiple Sclerosis (MS) sales grew 15.7% to €495 million, driven by Aubagio® performance in the U.S. and Europe. Year-to-date MS sales increased 24.8% to €1,540 million. Third-quarter Aubagio® sales increased 19.2% to €382 million driven by the U.S. (up 20.9% to €274 million). In Europe sales of Aubagio were up 16.0% to €86 million. Year-to-date Aubagio® sales increased 26.9% to €1,178 million. In the third quarter Lemtrada® sales were up 5.4% to €113 million, including €60 million in the U.S. (stable) and €40 million in Europe (up 10.8%). Year-to-date Lemtrada® sales increased 18.5% to €362 million.
bargainbob
03/11/2017
17:24
Bargain your right it’s the codes
dp1umb
03/11/2017
16:07
Bill hunt , the market forgot the liable bill imho , unless someone is stake building , I suspect the price to follow previous years. The issuing of the codes finally could bring support though. Suspect news of this before the 14th.
bargainbob
03/11/2017
15:42
In recent times the price has spiked before the reporting then retraced significantly after. Hope this is not the case this time around.
bill hunt
Chat Pages: Latest  199  198  197  196  195  194  193  192  191  190  189  188  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190619 17:35:38